These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24019330)

  • 1. Resistance emerges to second-generation antiandrogens in prostate cancer.
    Nelson WG; Yegnasubramanian S
    Cancer Discov; 2013 Sep; 3(9):971-4. PubMed ID: 24019330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.
    Joseph JD; Lu N; Qian J; Sensintaffar J; Shao G; Brigham D; Moon M; Maneval EC; Chen I; Darimont B; Hager JH
    Cancer Discov; 2013 Sep; 3(9):1020-9. PubMed ID: 23779130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).
    Korpal M; Korn JM; Gao X; Rakiec DP; Ruddy DA; Doshi S; Yuan J; Kovats SG; Kim S; Cooke VG; Monahan JE; Stegmeier F; Roberts TM; Sellers WR; Zhou W; Zhu P
    Cancer Discov; 2013 Sep; 3(9):1030-43. PubMed ID: 23842682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
    Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
    Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.
    Rajaram P; Rivera A; Muthima K; Olveda N; Muchalski H; Chen QH
    Molecules; 2020 May; 25(10):. PubMed ID: 32456317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.
    Bambury RM; Rathkopf DE
    Urol Oncol; 2016 Aug; 34(8):348-55. PubMed ID: 26162486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
    Wang R; Lin W; Lin C; Li L; Sun Y; Chang C
    Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor-related micro RNAs in prostate cancer and their role in antiandrogen drug resistance.
    Rezaei S; Mahjoubin Tehran M; Sahebkar A; Jalili A; Aghaee-Bakhtiari SH
    J Cell Physiol; 2020 Apr; 235(4):3222-3234. PubMed ID: 31599460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer.
    Cerasuolo M; Maccarinelli F; Coltrini D; Mahmoud AM; Marolda V; Ghedini GC; Rezzola S; Giacomini A; Triggiani L; Kostrzewa M; Verde R; Paris D; Melck D; Presta M; Ligresti A; Ronca R
    Cancer Res; 2020 Apr; 80(7):1564-1577. PubMed ID: 32029552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of novel androgen receptor therapies in the real world: A nuanced approach.
    Dhawan M; Ryan CJ
    Urol Oncol; 2016 Aug; 34(8):340-7. PubMed ID: 27450893
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Özgür E; Celik AI; Darendeliler E; Gezer U
    Anticancer Res; 2017 Jul; 37(7):3631-3637. PubMed ID: 28668854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer.
    Dellis AE; Papatsoris AG
    Expert Opin Pharmacother; 2019 Feb; 20(2):163-172. PubMed ID: 30462924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide.
    Wallis CJD; Chandrasekar T; Goldberg H; Klotz L; Fleshner N; Satkunasivam R; Klaassen Z
    Eur Urol Oncol; 2018 Aug; 1(3):238-241. PubMed ID: 31102627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.
    Zhang Z; Cheng L; Li J; Farah E; Atallah NM; Pascuzzi PE; Gupta S; Liu X
    Cancer Res; 2018 Jun; 78(12):3147-3162. PubMed ID: 29700003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARN-509: a novel antiandrogen for prostate cancer treatment.
    Clegg NJ; Wongvipat J; Joseph JD; Tran C; Ouk S; Dilhas A; Chen Y; Grillot K; Bischoff ED; Cai L; Aparicio A; Dorow S; Arora V; Shao G; Qian J; Zhao H; Yang G; Cao C; Sensintaffar J; Wasielewska T; Herbert MR; Bonnefous C; Darimont B; Scher HI; Smith-Jones P; Klang M; Smith ND; De Stanchina E; Wu N; Ouerfelli O; Rix PJ; Heyman RA; Jung ME; Sawyers CL; Hager JH
    Cancer Res; 2012 Mar; 72(6):1494-503. PubMed ID: 22266222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer.
    Wu M; Zhang R; Zhang Z; Zhang N; Li C; Xie Y; Xia H; Huang F; Zhang R; Liu M; Li X; Cen S; Zhou J
    Elife; 2023 Jan; 12():. PubMed ID: 36656639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the androgen receptor.
    Friedlander TW; Ryan CJ
    Urol Clin North Am; 2012 Nov; 39(4):453-64. PubMed ID: 23084523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cheminformatics Modeling of Adverse Drug Responses by Clinically Relevant Mutants of Human Androgen Receptor.
    Paul N; Carabet LA; Lallous N; Yamazaki T; Gleave ME; Rennie PS; Cherkasov A
    J Chem Inf Model; 2016 Dec; 56(12):2507-2516. PubMed ID: 28024400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.